GPCR/G protein

All GPCRs share a common seven trans-membrane structure. GPCRs are associated with heterotrimeric G-proteins which are GTP-binding proteins made of alpha, beta, and gamma subunits. When a ligand binds to GPCR, it activates the attached G-protein, the GDP is replaced with GTP. The activated G-protein then dissociates into an alpha and a beta-gamma complex which activates downstream signaling pathways. These intracellular signaling pathways include cAMP/PKA, calcium/NFAT, phospholipase C, protein tyrosine kinases, MAP kinases, PI-3-kinase, nitric oxide/cGMP, Rho, and JAK/STAT.
GPCRs are one of the most important therapeutic targets for various diseases, over 30% of all modern medicinal drugs target this family. Aberrant GPCR functions are involved in pathological conditions such as neurological, immunological and hormonal disorders. A large number of GPCRs have been identified, but whose ligands are not known, are classified as orphan receptors.
-  
B1341 NebivololSummary: Highly selective β1-adrenoceptor antagonist -  
B6923 PSB 10 hydrochlorideSummary: human adenosine A3 receptor antagonist -  
C3352 R-1 Methanandamide PhosphateSummary: CB1 receptor agonist -  
B1204 Ondansetron hydrochloride dihydrateSummary: 5-HT3 receptor antagonist -  
B1340 Naphazoline HClSummary: Adrenergic receptor agonist -  
B6922 PSB 1115Summary: human A2B adenosine receptor antagonist -  
C3113 SR 144528Summary: CB2 receptor inverse agonist -  
B1203 Iloperidone hydrochlorideSummary: D(2)/5-HT(2) receptor antagonistis -  
B1339 Metoprolol TartrateSummary: β1-adrenergic blocking agent -  
B6899 GR 79236Summary: adenosine A1 receptor agonist 
